IL17A and myeloid sarcoma: The IL-17 concentrations were significantly decreased in patients treated with IFN-β, methylprednisolone or both drugs as compared with untreated MS patients (P < 0.050, P < 0.020 and P < 0.050, respectively) (Table 4).